Clinical Trial

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-11-12; most recent amendment 2025-08-04.
Status change: Recruiting → Active, Not Recruiting 2024-07-08
Status change: Not Yet Recruiting → Recruiting 2021-07-13
Trial Details
NCT Number NCT04635189
Lead Sponsor University of Rochester
Conditions Multiple Myeloma
Enrollment 28 participants
Start Date 2021-07-27
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-08